Collaborations Pharmaceuticals Awarded an NIH Diversity Supplement and Accepted into I-Corps 

Raleigh, North Carolina – National Institute of Neurological Diseases (NINDS) at the National Institutes of Health has awarded $127,300 to Collaborations Pharmaceuticals, Inc. (CPI) under the Research Supplements to Promote Diversity in Health-Related Research Program. In addition, they were also accepted into the I-Corps program. Both of these awards relate to the SBIR “Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses”. 

“Collaborations Pharmaceuticals, Inc. recognizes the importance of having a diverse workforce and this diversity supplement provides further support for our recently awarded SBIR on Batten Disease. Additionally, the I-Corps™ at NIH program will provide us with training on how to translate technologies and help to develop our commercialization plan and strategies for this project” said Sean Ekins, PhD, chief executive officer of CPI.

 “We are very grateful to NIH-NINDS for their continued support on this project aiming to develop a treatment for a rare disease,” Ekins said. 


About Collaborations Pharmaceuticals, Inc.

Collaborations Pharmaceuticals, Inc. performs research and development on innovative therapeutics for multiple rare and infectious diseases. We partner with academics or companies to identify and translate early preclinical to clinical stage assets. We have considerable experience of preclinical and computational approaches to drug discovery and toxicity prediction. We have developed software for data curation and machine learning called Assay Central (

For more information, please visit


Contact information CPI

Sean Ekins, Ph.D., D.Sc.

CEO and Founder,

Collaborations Pharmaceuticals, Inc.

840 Main Campus Drive, Lab 3510,

Raleigh, NC 27606

Tel 215-687-1320